Clinical Research Directory
Browse clinical research sites, groups, and studies.
MitoQ for Fatigue in Multiple Sclerosis (MS)
Sponsor: VA Office of Research and Development
Summary
The purpose of this study is to determine whether MS patients who receive Oral mitoquinone (MitoQ) have less fatigue than those receiving a placebo. A comparison between patient's fatigue scored at baseline and fatigue scored 12 weeks after drug initiation will assess if MitoQ has a significant change in fatigue.
Official title: MitoQ for Fatigue in Multiple Sclerosis: A Placebo Controlled Trial
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
45
Start Date
2020-04-01
Completion Date
2026-03-31
Last Updated
2026-03-17
Healthy Volunteers
No
Conditions
Interventions
20 mg MitoQ
a third of subject will receive 20mg of oral MitoQ
Placebo
Subject will receive Placebo
40mg of MitoQ
a third of subjects will receive 40mg of MitoQ
Locations (1)
VA Portland Health Care System, Portland, OR
Portland, Oregon, United States